| Date | Title | Description |
| 27.09.2025 | Sparrow Pharmaceuticals: $95 Million Series B Raised For Advancing Targeted Therapy For Type 2 Diabetes | Sparrow Pharmaceuticals, a company focused on developing therapies for cardiometabolic conditions, recently announced the successful completion of a Series B financing round, raising an impressive $95 million. This significant investment wa... |
| 24.09.2025 | Sparrow Pharmaceuticals Raises $95M in Series B Financing | Sparrow Pharmaceuticals, a Portland, OR-based cardiometabolic therapeutics company, raised $95M Series B financing.
The round was co-led by RA Capital Management and Forbion with participation from existing investors including OrbiMed, Rive... |
| 05.09.2025 | Wugen Secures $115M: Off-the-Shelf CAR-T Fuels Cancer Fight | Wugen, a St. Louis-based biotech, secured $115 million in new funding. Fidelity Management led the significant investment round. The capital propels WU-CART-007, Wugen's cutting-edge allogeneic CAR-T cell therapy. This innovative "off-... |
| 04.09.2025 | Wugen: $115 Million Raised To Advance CAR-T For T-Cell Cancers | Wugen, a clinical-stage biotechnology company based in St. Louis, has announced the closing of a $115 million equity financing round. The investment, led by Fidelity Management & Research Company and joined by a consortium of life scien... |
| 28.08.2025 | Wugen Raises $115M in Funding | Wugen, a St. Louis, MO-based clinical-stage biotechnology company, raised $115M in funding.
The round was led by Fidelity Management and Research Company, with participation from RiverVest Venture Partners, Lightchain Capital, Abingworth, I... |
| 27.04.2025 | Biolinq: $100 Million Series C Funding Raised For Advancing Biowearable Platform For Metabolic Health | Biolinq, a healthcare technology company pioneering precision multi-analyte biosensors to improve metabolic health, announced a $100 million Series C funding round led by Alpha Wave Ventures. Existing investors RiverVest Venture Partners, A... |
| 23.04.2025 | Biolinq's $100 Million Leap: A New Era for Diabetes Management | In the world of health technology, innovation is the lifeblood. Biolinq, a California-based company, has just injected a hefty $100 million into its vision for the future of diabetes management. This Series C funding round, led by Alpha Wav... |
| 22.04.2025 | Biolinq raises $100M for intradermal glucose sensor for type 2 diabetes | Photo courtesy of Biolinq
Biolinq, a health technology company developing precision multi-analyte wearable biosensors for metabolic health, announced it secured $100 million in Series C funding.
Alpha Wave Ventures led the round with partic... |
| 22.04.2025 | Biolinq Raises $100M to Expand Biowearable Platform for Metabolic Health | What You Should Know:
– Biolinq, a healthcare technology company focused on developing precision multi-analyte biosensors to improve metabolic health raises $100M in Series C financing round led by Alpha Wave Ventures, with participation fr... |
| 29.01.2025 | Atalanta Therapeutics: A New Dawn in Neurological Treatments | Atalanta Therapeutics is making waves in the biotech ocean. This Boston-based company has just secured $75 million in Series B funding, a lifeline for its ambitious plans to tackle neurological diseases. The funding round was led by EQT Lif... |
| 28.01.2025 | EQT Life Sciences leads USD 97 million Series B in Atalanta Therapeutics, a biotech firm developing treatments for epilepsy and Huntington’s disease | EQT Life Sciences leads USD 97 million Series B in Atalanta Therapeutics, a biotech firm developing treatments for epilepsy and Huntington’s disease
Tue, Jan 28, 2025 13:00 CET Report this content
Atalanta Therapeutics is pioneering RNA int... |
| 21.01.2025 | Alleviant Medical: $90 Million Raised For Developing No-Implant Atrial Shunt For Heart Failure | Alleviant Medical – a privately held medical device company developing a no-implant atrial shunt for heart failure – announced a $90 million financing to fund its second pivotal trial. The round was led by Gilde Healthcare, and it also incl... |
| 06.04.2024 | Biolinq Revolutionizes Glucose Monitoring with $58M Funding Boost | Biolinq, a San Diego-based healthcare technology company, secures $58M in funding to advance its innovative continuous glucose monitoring patch. Led by Alpha Wave Ventures, the funding will support completion of a pivotal clinical trial and... |
| 04.04.2024 | Biolinq Secures $58M to Advance Continuous Glucose Monitoring Patch | What You Should Know:
– Biolinq, a provider of precision wearable biosensors for metabolic health secures $58M led by Alpha Wave Ventures. The round will include participation from Niterra’s corporate venture capital fund jointly operated w... |
| 19.03.2024 | Engrail Therapeutics raises $157M Series B | Engrail Therapeutics, a precision neuroscience company focused on the development of transformational therapies to improve the lives of patients, today announced that it has closed an oversubscribed $157 million Series B financing round.
Th... |
| 07.09.2022 | Roche shells out $250M to acquire Good Therapeutics and its preclinical oncology program | Roche announced Wednesday that it is paying $250 million in cash to acquire Good Therapeutics, a Seattle-based preclinical biotech company.
Good has raised a little over $30 million since it was founded in 2016. The company is focused on cy... |
| 24.03.2021 | RiverVest Venture Partners Closes $275 Million Life Sciences Fund | Oversubscribed fund to continue investing in high-impact biopharma and medical device innovation
ST. LOUIS–(BUSINESS WIRE)–March 24, 2021–
RiverVest Venture Partners, a leading venture capital firm, announced today the closing of its RiverV... |
| 24.03.2021 | RiverVest Venture Partners Closes $275 Million Life Sciences Fund | ST. LOUIS--(BUSINESS WIRE)--Mar 24, 2021--
RiverVest Venture Partners, a leading venture capital firm, announced today the closing of its RiverVest Venture Fund V, L.P. (“Fund V”), with $275 million of capital commitments in an oversubscrib... |
| 23.03.2021 | RiverVest Venture Partners Closes Fund V, At $275M | RiverVest Venture Partners, a St. Louis-based venture capital firm, closed its RiverVest Venture Fund V, L.P., at $275m.
Fund V is RiverVest’s largest fund to date, with commitments from a wide range of institutional investors, as well as f... |
| 17.11.2020 | EXCLUSIVE: WeedOUT closes Series A at $4.2m; appoints former Monsanto M&A chief | Israeli bio-herbicide maker WeedOUT has completed the final close of its Series A round, raising $4.22 million in total across two tranches.
Syngenta Ventures led the round, joining the first close of $3 million in February this year. Other... |
| 11.10.2018 | Term Sheet — Thursday, October 11 | LAWLESS
Good morning, Term Sheet readers.
Paid Content You can't secure what you can't see From ExtraHop
Bird, the electric scooter startup that raised more than $400 million, operated in five cities worldwide in May. Now, in the second wee... |
| 23.01.2017 | Adarza BioSystems Raises $17M Series C | Adarza BioSystems, Inc., a leading next generation innovator in label-free, multiplex assays, announced today that it has closed a $17M Series C financing.
Proceeds from the financing will be used to further expand production capacity in it... |
| 23.01.2017 | Adarza BioSystems Raises $17M Series C | Adarza BioSystems, Inc., a leading next generation innovator in label-free, multiplex assays, announced today that it has closed a $17M Series C financing.
Proceeds from the financing will be used to further expand production capacity in it... |
| 15.12.2016 | Term Sheet — Thursday, December 15 | TRUMP, VERIHOO, LAYOFF WATCH
Yesterday the Titans of Tech met with Trump, drank his Trump-branded water, rode his Trump-gold elevator. A few notes for those of you that didn’t spend the afternoon refreshing Twitter for new photos of CEOs lo... |
| 07.04.2016 | RiverVest Venture Partners Hires Nancy A. Hong as Managing Director | Life sciences venture capital firm RiverVest Venture Partners hired Nancy A. Hong, Ph.D., as managing director.
The firm also announced that it is opening an office in San Diego where Hong will work with RiverVest Managing Director Niall O’... |
| 11.11.2015 | Daily funding roundup - November 11, 2015 | Amplyx Pharmaceuticals bagged $40.5M; Perfecto Mobile secured $35M; EventBoard raised $6.5M funding
Last week an article in New York Magazine outlined a growing problem in businesses: the fight over meeting space. There are now 25 million m... |
| 06.05.2015 | RiverVest Venture Partners Closes Third VC Fund at $80.2M | St. Louis, MO-based life sciences venture capital firm RiverVest Venture Partners closed its third fund at $80.2m.
RiverVest Venture Fund III, L.P. will continue the firm’s strategy investing in early-stage life science companies. Since its... |
| 26.06.2014 | RiverVest finds success in blowing the dust off old compounds | This unconventional strategy is in line with the recommendations of National Institutes of Health head Francis Collins, who tasked drug companies to “open their freezers” and seek out drugs that have passed safety trials but may have failed... |
| 13.03.2014 | Does this belong in my pitch deck? VCs weigh in (Part 2) | On the other side of the table were investors Mike Stubler of Draper Triangle Ventures, Karen Spilizewski of RiverVest and Steve Haynes of Glengary. Below are some highlights.
I have a personal interest in my company/product. Should I talk ... |
| 30.10.2013 | Securus Medical Group Lands $6.5M in Series B |
CLEVELAND, OH, Privately held medical device company, announced the initial closing of a $6.5 million Series B financing led by new investor 3X5 Special Opportunity Fund.
>> Click here for more funding data on Securus Medical Group... |
| 29.10.2013 | Ohio medical device firm finds new CEO and $6.5M for thermographic mapping system | Along with the funding, Securus named a new president and CEO: Steven Girouard, a former vice president of emerging technologies at Johnson & Johnson who has also worked at Guidant Corp. and Cleveland Clinic.
Securus’s last big funding ... |
| 08.05.2013 | Lumena Pharmaceuticals Secures $23M in Series A Financing | Lumena Pharmaceuticals, a San Diego, CA-based developer of oral therapeutics for rare liver diseases, secured $23m in Series A financing.
Backers included Pappas Ventures, which founded the company in 2011, RiverVest Venture Partners and Al... |
| 11.01.2013 | Durham startup developing stents for bifurcated lesions garners $24 million | Tryton’s Side Branch stent is made of a cobalt chromium alloy. It is placed in the side branch along with a conventional drug-eluting stent in the main vessel.
“The company’s innovative stent system for coronary bifurcations is expected to ... |
| 08.01.2013 | Tryton Medical to Raise $24M Financing | Tryton Medical, Inc., a Durham, N.C.-based developer of stents designed to treat bifurcation lesions, held an initial closing of an aggregate $24m financing.
Backers included existing investors PTV Sciences, which led the round, RiverVest V... |
| 17.12.2012 | Allakos Completes $32M Series A Financing | Allakos Inc., a San Francisco Bay Area-based biotechnology company, has completed a $32m Series A financing.
The round was led by Novo Ventures with participation from Alta Partners, RiverVest Venture Partners and the Roche Venture Fund.
In... |
| 18.07.2012 | Pain device maker Neuros Medical’s $3.5M round led by Boston Scientific, Glengary | Last year, the company completed the first in-man feasibility study of its device and it is now in the process of a pilot clinical trial in patients experiencing pain from amputated limbs. That trial should yield results by year’s end, said... |
| 20.02.2012 | Diabetes drug developer Lumena raises $2.5M; compound regulates blood sugar | The Research Triangle Park company is developing a new diabetes treatment based on the role bile acids play as signaling agents in the gastrointestinal tract. When Lumena launched its fundraising efforts last year, CEO Michael Grey explaine... |
| 14.02.2012 | Chronic pain device from Neuros Medical gets new investor | Neuros is developing a device that uses a pacemaker-sized generator and an electrode to stimulate nerves to block pain from amputations — sometimes called stump pain — without the use of drugs. In November, Neuros received regulatory approv... |
| 21.12.2011 | C.R. Bard buys Lutonix’s drug-coated balloon catheter for PAD for $225M | “In our evaluations, Lutonix has the only third-generation, drug-coated balloon technology,” Bard’s Chairman and CEO Timothy Ring said in a statement. “They also have a significant lead with respect to a U.S. launch.”
Moxy received the CE M... |
| 02.08.2011 | Securus Medical Group Raises $750K in Series A Funding | Securus Medical Group, a Cleveland, OH-based company that develops a product that provides real-time temperature mapping within a hollow body cavity, has raised $750k of a $1.5m Series A funding round.
Investors include RiverVest Venture Pa... |
| 15.07.2011 | Cardiac device firm developing esophagus heat map moves to Cleveland | Securus’ technology would provide doctors with a real-time thermal map of the esophagus while they’re performing ablations, helping reduce the risk of fistulas.
Securus was founded in the Boston area, but moved to Cleveland after receiving ... |
| 08.01.2010 | Salient Surgical Tech banks $15 million from new venture round | Financial backers of Salient Surgical Technologies Inc. are again stepping up to protect their investments, ponying up $15 million in new funding while they wait for an eventual liquidity event.
The deal is the Portsmouth, N.H.-based compan... |
| 14.10.2009 | Ohio House Democrats introduce bill to expand Ohio Capital Fund by $100 million | “We cannot move Ohio forward without a keen focus on making sure our economy is growing,” Williams said in a written statement. “An important component of that growth is the expansion of the Ohio Capital Fund, which provides private invest... |
| - | RiverVest finds success in blowing the dust off old compounds | Niall O’Donnell fancies himself an archaeologist of the pharmaceutical persuasion. His firm, RiverVest Ventures, is scoping out the failed and forgotten drugs of big pharma, building companies to repurpose these benched meds for new indicat... |
| - | Ohio House Democrats introduce bill to expand Ohio Capital Fund by $100 million | COLUMBUS, Ohio — Two Ohio representatives today introduced legislation that would give the Ohio Capital Fund at least $100 million more to invest in the state’s growth industries, such as health care.
Rep. Jay Goyal, a Mansfield Democrat,... |
| - | Ohio medical device firm finds new CEO and $6.5M for thermographic mapping system | Securus Medical Group said today it’s got a new CEO and a new investor backing it as part of a $6.5 million Series B.
According to the company, the cash, and the new leadership, will allow it to continue development of a thermographic mappi... |
| - | Pain device maker Neuros Medical’s $3.5M round led by Boston Scientific, Glengary | Neurostimulation device company Neuros Medical Inc. has landed $3.5 million in its second round of funding from a handful of investors including medical device powerhouse Boston Scientific (NYSE:BSX).
The company’s device, called the Electr... |
| - | Diabetes drug developer Lumena raises $2.5M; compound regulates blood sugar | Diabetes treatment developer Lumena Pharmaceuticals has secured the $2 million it needs to start clinical trials and a little bit extra for good measure.
The company’s first round of investment was oversubscribed and led to a haul of $2.5 m... |
| - | Durham startup developing stents for bifurcated lesions garners $24 million | Tryton Medical, a Durham, North Carolina, startup developing coronary stents to treat bifurcated lesions announced earlier this week that the company has had an initial closing of a $24 million funding round. A regulatory filing shows the c... |
| - | Cardiac device firm developing esophagus heat map moves to Cleveland | A medical device company focused on specific minimally invasive cardiac surgeries has moved from Boston to Cleveland hoping to collect $1.5 million and develop its product.
Securus Medical Group is well on the way to closing that round. It ... |
| - | Chronic pain device from Neuros Medical gets new investor | Neurostimulation startup Neuros Medical, which is developing a device to block the chronic pain of amputees, has secured a new investor in RiverVest Venture Partners.
RiverVest will participate in Neuros’ next funding round, which is expect... |
| - | C.R. Bard buys Lutonix’s drug-coated balloon catheter for PAD for $225M | C.R. Bard Inc. will acquire the Maple Grove, Minnesota startup Lutonix Inc. for its novel drug-coated balloon catheter for treatment of peripheral artery disease.
New Jersey-based medical device firm Bard announced Tuesday it would pay $225... |
| - | Does this belong in my pitch deck? VCs weigh in (Part 2) | Each year, one courageous startup takes to the podium at the Ohio Venture Association’s annual summit to pitch the business to three investors and dozens of others watching from the crowd. It’s part of a fantastic, interactive panel that’s ... |
